UNSPSC 51391730: Pirbuterol

This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C12H20N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OG645J8RVW, chemically known as ethanol, 2-tert-butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)- but generally known as pirbuterol, which bears US NIH Compound Identifier 4845. European Medicines Agency schedules Pirbuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09900MIG.

UNSPSC 51391730 Pirbuterol is a Commodity code that nominally designates individual pharmaceutical products, but the recent state and local opportunities tagged to it show a disconnect from the code's narrow scope. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking procurement of naloxone and safe drug deactivation systems — not pirbuterol — with annual volumes of 1,900 units of naloxone and 800 deactivation units, quarterly deliveries, and a two-year initial contract term with one-year renewal option. The Texas Health and Human Services Commission concurrently issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting between the state's pharmacy benefit program and manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The code shows little relevant recent activity aligned with pirbuterol procurement specifically; the opportunities present represent broader pharmaceutical supply and pharmacy program structure rather than acquisition of a named pharmaceutical product.

The issuing bodies span a county health system (Seminole County) and a state health and human services commission (Texas HHS), indicating activity across both local health authorities and state-level pharmacy administration. Geographic spread is limited to Florida and Texas in the recent opportunities block. The Seminole County IFB (due July 26, 2023, though posted in June 2026) specifies electronic bidding through the county's e-Procurement Portal, requires drug-free workplace and E-Verify compliance, and carries a three-month probationary termination clause; the Texas RFI is exploratory in nature and does not establish binding timelines, award values, or formal evaluation criteria. The mismatch between the code's nominal pharmaceutical scope and the actual procurement activity — focused on naloxone (a different drug class) and pharmacy program infrastructure — suggests this code may be misapplied or reflects upstream taxonomy errors in how opportunities are tagged.